Viyash Scientific share price today

Viyash Scientific Ltd's share price was ₹219.45 at the close on 3 November 2026. It has been rising for 74 weeks. That is 6.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹188 and ₹294, and at that close it sat 30% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Viyash Scientific Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 9 weeks running.

Over the last 11 years the share price moved +35% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1 points in one quarter, profit up on a year earlier for 11 quarters in a row (every quarter we can compare) and revenue up on a year earlier for 9 quarters in a row.

1. Promoters cut their stake by 12.1 points in one quarter

   From 61.3% to 49.2% in the September 2026 quarter.

2. Profit up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter profit was ₹79 crore, +113.5% on a year earlier.

   Why: Profit rose because the US human formulations business became much more profitable.

   Next results: check whether the remaining ESOP expense is around Rs 40 crore as management said.

   From the earnings call on 12 Aug 2026.

3. Revenue up on a year earlier for 9 quarters in a row

   In the June 2026 quarter revenue was ₹946 crore, +19.4% on a year earlier.

   Why: Revenue rose because animal-health products grew across regions on new launches and wider reach.

   Next results: check whether API orders come back and Vizag starts selling without another raw-material buying pause.

   From the earnings call on 12 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Viyash Scientific reported revenue of ₹946 crore, up 19.4% from ₹792 crore a year earlier, and a profit of ₹79.0 crore, up 113.5% from ₹37.0 crore.

Viyash Scientific results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Viyash Scientific's management discussed these results on a call held on 12 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Viyash Scientific closed at ₹219.45 on 3 November 2026, up 2.3% from ₹214.61 a year earlier (31 October 2025) and up 21.2% over five years. Its highest weekly close since March 2016 was ₹303.45 on 16 July 2021.

Viyash Scientific share price: then and now

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 3 November 2026.

3 Nov 2026: Viyash Scientific closed at ₹219.45, up 7.9% on the week and down 5.3% on the month. 12 Aug 2026: Viyash Scientific held its results call for April to June 2026. Management guided: Consolidated operating margin around 20-22%, with US human-formulations margin expected to continue at the current level.

Earlier

• Results for April to June 2026: Revenue up 19.4% and profit up 113.5% on a year earlier.

Viyash Scientific paid no dividend in the 12 months to 4 November 2026. The last was a dividend of ₹0.50 a share, ex-date 8 September 2021.

Viyash Scientific dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Not in its latest year. Viyash Scientific Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 4 November 2026.

On the call for April to June 2026, held on 12 August 2026, Viyash Scientific's management guided: Consolidated operating margin around 20-22%, with US human-formulations margin expected to continue at the current level.

“We are not going to acquire a business simply because our balance sheet is strong and we want to add numbers. That is not the plan.”Dr. Haribabu, on the call for April to June 2026

What management guided

• FY27 revenue assumption approximately ₹4,000 crore, with API contributing 40-45%; overall API growth around 13-15% and animal-health API above 20%.
• Europe growth 18-20% on an INR basis in FY27, excluding BioForLife; closing expected in 2-3 months and wider registrations over 18-24 months.
• Remaining FY27 ESOP expense around ₹40 crore; goodwill amortization around ₹10-11 crore next quarter and then ceases from Q3.
• Minority interests in the US and Spain planned for full acquisition within 2 years; minority share expected around 15-17% of profit.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 12 August 2026.

When Viyash Scientific reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: API order recovery and Vizag commercialization to translate into the next quarter's print without another raw-material-driven procurement pause.

Viyash Scientific is on one of our India lists: Pharma stocks.

Viyash Scientific Ltd earned ₹79.0 Cr of net profit in the Jun 2026 quarter, +113.5% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹225 Cr. That is 8.4% of the quarter's revenue. The same quarter a year earlier earned ₹37.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹225 Cr (+1,306.3% on the year before).

Why profit moved: revenue changed +19.4% on a year earlier and the margin moved +4.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +451.7% and revenue +72.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Viyash Scientific Ltd reported ₹946 Cr of revenue in the Jun 2026 quarter, +19.4% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 10 years it has grown 18.9% a year on average. The last full year, FY26, came in at ₹3,420 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹3,574 Cr.

FY26 revenue was ₹3,420 Cr, +13.7% on the year before.

Recent pace: the last four quarters grew +72.4% on average, against 18.9% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +52.9%, against +58.3% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +181.1%, against +336.7% a year (rolling over).

Viyash Scientific Ltd's operating margin was 19.0% in the Jun 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 0.8% and 19.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.9 percentage points on the year while gross margin changed +2.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 244% of Viyash Scientific Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹323 Cr of operating cash against ₹225 Cr of profit. After ₹261 Cr of spending on assets, ₹62.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 244% of profit came in as cash: the cash cycle got 48 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 3.8× depreciation over three years. The next section checks what that spending is building.

Viyash Scientific Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 160 days in FY26, up from 112 days in FY21. It spent ₹2,048 Cr on assets over the last 3 years. Customers take 112 days to pay, and stock sits for 188 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹3,420 Cr, each day of that cycle ties up about ₹9.4 Cr, so roughly ₹1,499 Cr is tied up in the business at any time.

FY26: customers took 112 days to pay and stock sat for 188 days, about 6.2 months of sales sitting as stock, for a full cycle of 160 days, longer than FY21's 112.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 188 days. Customers pay about 112 days after that. Suppliers are paid at 140 days. Together that makes the 160-day cycle.

Spending on assets: ₹2,048 Cr over the last 3 years, against ₹535 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹70.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Viyash Scientific Ltd's P/E is 43.8×, near the low end of its own history: it has been lower only 27% of the time. Its usual P/E (the middle reading) is 58.9×, over 9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹5.76.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.